UroGen Pharma Ltd. (URGN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the URGN SEC filings page.
UroGen Pharma Ltd. (URGN) reported $188.7M in revenue over the twelve months to Jun 30, 2026, up 100.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is expanding, but cost growth is outrunning commercialization, leaving a cash-funded development model with worsening losses.
From FY2023 to FY2025, revenue grew33.7% while gross margin remained around89.0% , showing that product-level economics were broadly stable. Yet operating margin deteriorated to-113.7% as operating cash flow reached-$162M in FY2025, indicating overhead and investment expanded faster than gross profit.
FY2025 operating expenses reached
Negative equity of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of UroGen Pharma Ltd.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
UroGen Pharma Ltd. held $160.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $162.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and UroGen Pharma Ltd. scores 33/100 among other emerging companies.
UroGen Pharma Ltd. had 49M shares outstanding at the end of fiscal year 2025, against 46M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and UroGen Pharma Ltd. scores 36/100 among other emerging companies.
UroGen Pharma Ltd. spent $67.1M on research and development in fiscal year 2025, which was 28.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and UroGen Pharma Ltd. scores 62/100 among other emerging companies.
UroGen Pharma Ltd. reported revenue of $109.8M in fiscal year 2025, against $90.4M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and UroGen Pharma Ltd. scores 61/100 among other emerging companies.
UroGen Pharma Ltd.'s operations used $162.4M of cash in fiscal year 2025, against $96.8M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and UroGen Pharma Ltd. scores 18/100 among other emerging companies.
UroGen Pharma Ltd.'s cash, cash equivalents and investments came to $160.1M at the end of fiscal year 2025, against $305.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and UroGen Pharma Ltd. scores 44/100 among other emerging companies.
UroGen Pharma Ltd. scores -3.87, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.8B) relative to total liabilities ($305.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
UroGen Pharma Ltd. passes 1 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
UroGen Pharma Ltd. reported a net loss of $153.5M while operations used $162.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
UroGen Pharma Ltd. reported an operating loss of $124.9M against $15.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
UroGen Pharma Ltd. generated $72.5M in revenue in Q2 2026. This represents an increase of 199.2% from the same quarter a year earlier. Against the prior quarter it is up 42.2%.
UroGen Pharma Ltd.'s EBITDA was $211K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.5% from the same quarter a year earlier. Against the prior quarter it is up 101.0%.
UroGen Pharma Ltd. reported -$14.4M in net income in Q2 2026. This represents an increase of 71.3% from the same quarter a year earlier. Against the prior quarter it is up 39.1%.
Not reported for Q2 2026.
Cash & Balance Sheet
UroGen Pharma Ltd. recorded an outflow of $33.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 17.3% from the same quarter a year earlier. Against the prior quarter it is up 27.1%.
UroGen Pharma Ltd. held $79.1M in cash against $188.7M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
UroGen Pharma Ltd.'s gross margin was 90.9% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 5.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.9 percentage points.
UroGen Pharma Ltd.'s operating margin was 0.1% in Q2 2026, reflecting core business profitability. Against the prior quarter it is up 39.9 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
UroGen Pharma Ltd.'s net profit margin was -19.8% in Q2 2026, showing the share of revenue converted to profit. Against the prior quarter it is up 26.5 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2026.
Capital Allocation
UroGen Pharma Ltd. invested $17.3M in research and development in Q2 2026. This represents a decrease of 8.3% from the same quarter a year earlier. Against the prior quarter it is up 11.1%.
UroGen Pharma Ltd. invested $60K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 57.4% from the same quarter a year earlier. Against the prior quarter it is up 11.1%.
Not reported for Q2 2026.
URGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72.5M+199.2% | $51.0M+151.6% | $37.8M+54.0% | $27.5M+9.0% | $24.2M+10.8% | $20.3M+7.8% | $24.6M+4.4% | $25.2M+20.9% |
| Cost of Revenue | $6.6M+85.1% | $4.1M+77.6% | $3.3M | $3.3M+33.6% | $3.5M+59.3% | $2.3M+34.8% | N/A | $2.5M+3.6% |
| Gross Profit | $65.9M+218.8% | $46.8M+161.2% | $34.5M+56.4% | $24.2M+6.4% | $20.7M+5.3% | $17.9M+5.1% | $22.1M+4.0% | $22.8M+23.1% |
| R&D Expenses | $17.3M-8.3% | $15.6M-21.5% | $14.3M | $14.0M+23.4% | $18.9M+22.8% | $19.9M+28.2% | N/A | $11.4M+11.0% |
| SG&A Expenses | $48.4M+12.1% | $51.5M+47.2% | $39.3M | $37.6M+29.9% | $43.2M+43.7% | $35.0M+28.1% | N/A | $28.9M+33.0% |
| Operating Income | $111K+100.3% | -$20.3M+45.1% | -$19.1M | -$27.4M-56.1% | -$41.4M-60.4% | -$36.9M-43.4% | N/A | -$17.5M-30.0% |
| EBITDA | $211K+100.5% | -$20.2M+45.2% | -$19.1M | -$27.3M-56.4% | -$41.3M-60.6% | -$36.8M-43.8% | N/A | -$17.4M-31.2% |
| Interest Expense | $4.9M+18.3% | $4.2M+2.9% | $3.8M | $3.4M+24.0% | $4.1M+19.4% | $4.1M+66.2% | N/A | $2.7M-28.7% |
| Income Tax | $5.6M+454.6% | -$4.8M-1317.3% | -$275K | -$1.1M-1258.2% | $1.0M+2571.1% | $392K+625.9% | N/A | $91K+1111.1% |
| Net Income | -$14.4M+71.3% | -$23.6M+46.2% | -$26.4M+29.7% | -$33.3M-40.9% | -$49.9M-49.5% | -$43.8M-35.8% | -$37.5M-44.2% | -$23.7M-8.2% |
| EPS (Basic) | -$0.28+73.3% | -$0.47+48.9% | -$0.53+33.8% | -$0.69-35.3% | -$1.05-28.0% | -$0.92-5.7% | -$0.80-11.1% | -$0.51+25.0% |
Not reported in any period shown, so not listed: EPS (Diluted), Diluted Shares (Avg).
URGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $252.6M+21.0% | $253.7M+2.5% | $200.5M-29.8% | $185.0M-38.7% | $208.7M-25.9% | $247.6M+23.5% | $285.7M+60.2% | $301.9M+55.9% |
| Current Assets | $235.4M+19.6% | $237.5M+0.1% | $186.0M-32.6% | $168.5M-42.9% | $196.9M-29.4% | $237.2M+20.5% | $276.1M+63.2% | $295.1M+62.0% |
| Cash & Equivalents | $79.1M-14.8% | $110.0M+5.7% | $110.7M-35.6% | $90.0M-27.9% | $92.9M-57.8% | $104.0M-20.9% | $172.0M+81.0% | $124.9M+4.7% |
| Short-Term Investments | $30.2M-63.7% | $39.7M-64.5% | $49.3M-55.4% | $63.8M-58.6% | $83.1M+59.0% | $112.0M+116.6% | $110.7M+97.1% | $153.9M+178.4% |
| Inventory | $24.6M+245.0% | $20.9M+175.6% | $16.5M+78.4% | $8.3M+9.8% | $7.1M-4.2% | $7.6M+4.8% | $9.2M+62.6% | $7.6M+51.8% |
| Accounts Receivable | $88.8M+351.7% | $55.4M+182.2% | $33.1M+62.9% | $19.7M-13.6% | $19.6M+12.8% | $19.6M+38.7% | $20.3M+31.5% | $22.8M+77.5% |
| Long-Term Investments | $0-100.0% | $0-100.0% | $0-100.0% | $380K-91.8% | $4.6M+2181.8% | $4.5M+838.5% | $5.0M+11.6% | $4.6M-28.7% |
| Total Liabilities | $385.0M+27.4% | $377.9M+28.5% | $305.9M+3.9% | $300.5M+8.7% | $302.1M+20.1% | $294.1M+22.2% | $294.5M+20.9% | $276.4M+17.3% |
| Current Liabilities | $61.9M+30.2% | $50.6M+20.6% | $46.4M+1.0% | $42.2M+28.8% | $47.5M+38.9% | $42.0M+59.5% | $45.9M+47.2% | $32.8M+27.1% |
| Non-Current Liabilities | $323.1M+26.9% | $327.3M+29.8% | $259.5M+4.4% | $258.2M+6.0% | $254.5M+17.1% | $252.1M+17.6% | $248.6M+17.1% | $243.6M+16.1% |
| Long-Term Debt | $188.7M+54.1% | $189.5M+55.2% | $122.2M+0.4% | $122.1M+0.3% | $122.5M+25.2% | $122.1M+25.1% | $121.7M+23.5% | $121.7M+23.5% |
| Total Equity | -$132.4M-41.8% | -$124.3M-167.5% | -$105.5M-1098.2% | -$115.4M-552.3% | -$93.4M-408.0% | -$46.5M-15.8% | -$8.8M+86.5% | $25.5M+160.8% |
| Retained Earnings | -$997.6M-10.8% | -$983.3M-15.7% | -$959.7M-19.0% | -$933.4M-21.4% | -$900.0M-20.8% | -$850.1M-19.5% | -$806.2M-18.7% | -$768.7M-17.7% |
Not reported in any period shown, so not listed: Goodwill.
URGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$33.0M+17.1% | -$45.3M-7.8% | -$38.3M-181.4% | -$42.3M-52.8% | -$39.8M-67.7% | -$42.0M-32.4% | -$13.6M-4.8% | -$27.7M-59.9% |
| Depreciation & Amortization | $100K0.0% | $75K+4.2% | $75K+10.3% | $100K0.0% | $100K0.0% | $72K-41.5% | $68K-64.2% | $100K-50.0% |
| Stock-Based Compensation | $5.3M+95.1% | $4.6M+50.8% | N/A | $3.0M-13.2% | $2.7M-23.2% | $3.1M+11.4% | N/A | $3.5M+56.9% |
| Capital Expenditures | $60K-57.4% | $54K+22.7% | $17K-85.2% | $87K-9.4% | $141K+67.9% | $44K | $115K+105.4% | $96K-4.0% |
| Free Cash Flow | -$33.1M+17.3% | -$45.4M-7.8% | -$38.3M-179.2% | -$42.4M-52.6% | -$40.0M-67.7% | -$42.1M-32.6% | -$13.7M-5.2% | -$27.8M-59.5% |
| Investing Cash Flow | $1.7M-94.1% | -$20.7M+20.3% | $27.7M-54.3% | $31.4M+129.4% | $28.4M+136.8% | -$26.0M-292.1% | $60.6M+634.4% | -$106.8M-26720.9% |
| Financing Cash Flow | $500K+68.9% | $65.2M+191676.5% | $31.3M+44007.0% | $8.3M-79.1% | $296K-99.7% | $34K-99.9% | $71K+77.5% | $39.6M-65.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
URGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.9%+5.6pp | 91.9%+3.4pp | 91.3%+1.4pp | 88.1%-2.2pp | 85.3%-4.5pp | 88.5%-2.3pp | 89.9%-0.3pp | 90.3%+1.6pp |
| Operating Margin | 0.1% | -39.8% | -50.5% | -99.7%-30.0pp | -171.2% | -182.3% | N/A | -69.6%-4.9pp |
| Net Margin | -19.8% | -46.3% | -69.7% | -121.3% | -206.2% | -216.5% | -152.7% | -93.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -92.8% |
| Return on Assets | -5.7%+18.3pp | -9.3%+8.4pp | -13.2%0.0pp | -18.0%-10.2pp | -23.9%-12.1pp | -17.7%-1.6pp | -13.1%+1.5pp | -7.8%+3.5pp |
| Current Ratio | 3.80-0.3x | 4.69-1.0x | 4.01-2.0x | 3.99-5.0x | 4.14-4.0x | 5.65-1.8x | 6.01+0.6x | 9.00+1.9x |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 4.77 |
| Asset Turnover | 0.29+0.2x | 0.20+0.1x | 0.19+0.1x | 0.15+0.1x | 0.120.0x | 0.080.0x | 0.090.0x | 0.080.0x |
| FCF Margin | -45.6% | -89.0% | -101.3% | -154.1% | -165.1% | -207.7% | -55.9%-0.4pp | -110.1% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$105.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| UroGen Pharma Ltd. URGN | FY2025 | $109.8M | -$153.5M | N/A | $1.8B | 42/100 |
| Spyre Therapeutics, Inc. SYRE | FY2025 | $0 | -$155.2M | N/A | $7.5B | — |
| EyePoint, Inc. EYPT | FY2025 | $31.4M | -$232.0M | N/A | $270.7M | 46/100 |
| Sana Biotechnology, Inc. SANA | FY2025 | N/A | -$244.2M | N/A | $740.9M | — |
| uniQure N.V. QURE | FY2025 | $16.1M | -$199.0M | N/A | $1.6B | 44/100 |
Where UroGen Pharma Ltd. Ranks
Frequently Asked Questions
What is UroGen Pharma Ltd.'s annual revenue?
UroGen Pharma Ltd. (URGN) reported $109.8M in total revenue for fiscal year 2025. This represents a 21.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is UroGen Pharma Ltd.'s revenue growing?
UroGen Pharma Ltd. (URGN) revenue grew by 21.4% year-over-year, from $90.4M to $109.8M in fiscal year 2025.
Is UroGen Pharma Ltd. profitable?
No, UroGen Pharma Ltd. (URGN) reported a net income of -$153.5M in fiscal year 2025.
What is UroGen Pharma Ltd.'s EBITDA?
UroGen Pharma Ltd. (URGN) had EBITDA of -$124.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does UroGen Pharma Ltd. have?
As of fiscal year 2025, UroGen Pharma Ltd. (URGN) had $110.7M in cash and equivalents against $122.2M in long-term debt.
What is UroGen Pharma Ltd.'s gross margin?
UroGen Pharma Ltd. (URGN) had a gross margin of 88.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is UroGen Pharma Ltd.'s free cash flow?
UroGen Pharma Ltd. (URGN) recorded an outflow of $162.7M in free cash flow during fiscal year 2025. This represents a -67.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is UroGen Pharma Ltd.'s operating cash flow?
UroGen Pharma Ltd. (URGN) recorded an outflow of $162.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are UroGen Pharma Ltd.'s total assets?
UroGen Pharma Ltd. (URGN) had $200.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are UroGen Pharma Ltd.'s capital expenditures?
UroGen Pharma Ltd. (URGN) invested $289K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does UroGen Pharma Ltd. spend on research and development?
UroGen Pharma Ltd. (URGN) invested $67.1M in research and development during fiscal year 2025.
What is UroGen Pharma Ltd.'s current ratio?
UroGen Pharma Ltd. (URGN) had a current ratio of 4.01 as of fiscal year 2025, which is generally considered healthy.
What is UroGen Pharma Ltd.'s return on assets (ROA)?
UroGen Pharma Ltd. (URGN) had a return on assets of -76.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is UroGen Pharma Ltd.'s P/E ratio?
UroGen Pharma Ltd. (URGN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.8B as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is UroGen Pharma Ltd.'s price-to-sales ratio?
UroGen Pharma Ltd. (URGN) trades at 9.5x sales, its market capitalization divided by revenue of $188.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.8B as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does UroGen Pharma Ltd.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, UroGen Pharma Ltd. (URGN) held $160.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $162.4M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is UroGen Pharma Ltd.'s debt-to-equity ratio negative or not reported?
UroGen Pharma Ltd. (URGN) has negative shareholder equity of -$105.5M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is UroGen Pharma Ltd.'s Altman Z-Score?
UroGen Pharma Ltd. (URGN) has an Altman Z-Score of -3.87, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is UroGen Pharma Ltd.'s Piotroski F-Score?
UroGen Pharma Ltd. (URGN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are UroGen Pharma Ltd.'s earnings high quality?
UroGen Pharma Ltd. (URGN) reported a net loss of $153.5M while operations used $162.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can UroGen Pharma Ltd. cover its interest payments?
UroGen Pharma Ltd. (URGN) reported an operating loss of $124.9M against $15.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is UroGen Pharma Ltd.?
UroGen Pharma Ltd. (URGN) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.